Jd. Lambris et al., THE 3RD COMPONENT OF XENOPUS COMPLEMENT - CDNA CLONING, STRUCTURAL AND FUNCTIONAL-ANALYSIS, AND EVIDENCE FOR AN ALTERNATE C3 TRANSCRIPT, European Journal of Immunology, 25(2), 1995, pp. 572-578
Although the third component of complement has been purified from two
amphibian species, Xenopus laevis and the axolotl, only limited inform
ation is available about its primary structure in these species. We no
w present (a) 95% of the cDNA sequence encoding C3 from a Xenopus laev
is/Xenopus gilli (Xenopus LG) hybrid (b) an analysis of the C3 convert
ase and factor I cleavage sites in Xenopus C3, and (c) evidence for an
alternative form of C3. The Xenopus LG sequence has a 57% nucleotide
and 52% amino acid sequence identity to human C3 and contains one pote
ntial N-glycosylation site in the P-chain. The deduced amino acid sequ
ence showed that the C3 convertase and factor I cleavage sites (Arg-Se
r) are conserved in Xenopus C3 and protein sequencing of Xenopus C3 fr
agments fixed on zymosan during complement activation demonstrated tha
t Xenopus C3 is indeed cleaved by C3 convertase and factor I at these
sites. Our screening of a liver cDNA library identified an unusual C3
clone with a deletion of 2502 bp, suggesting the presence of a novel C
3 transcript in Xenopus LG liver. The presence of this C3 transcript w
as confirmed by reverse transcription polymerase chain reaction using
Xenopus LG liver mRNA and specific oligonucleotide probes. This transc
ript encoded a putative 102-kDa protein comprising the beta-chain of C
3, together with the first 59 residues and the last 103 residues of th
e alpha-chain; it would therefore lack many of the ligand binding site
s found in the intact alpha-chain. However, the molecule may be an ana
log of a truncated C3 molecule that is found in the serum of allergic
dermatitis patients and acts as an inhibitor of eosinophil cytotoxicit
y and neutrophil adherence.